和鉑醫藥-B(02142.HK):兩產品已啟動商業化前期工作
和鉑醫藥-B(02142.HK)今日(10日)在聯交所主板上市,主席及首席執行官王勁松表示,公司產品線中已有一部分藥品處開發中後期,包括用於治療多種自身免疫性疾病的「巴托利單抗」,目前已取得四個臨床研究批件。而另一治療乾眼病藥品「特那西普」亦已獲內地批准進行三期註冊臨床。
他指,兩產品已啟動組建團隊等的商業化前期工作,相信隨著公司更多藥品陸續進入商業化階段,加上研開過程中的技術轉讓及授權,可帶來更多的商業回報,令公司有更佳的財務平衡。
王勁松又稱,公司著重差異化優勢及全球創新,認為是次在港上市令公司獲得更好的資源及發展。(ek/w)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.